Q1 2022 Earnings Estimate for Lantheus Holdings, Inc. Issued By Jefferies Financial Group (NASDAQ:LNTH)

Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating) – Equities researchers at Jefferies Financial Group dropped their Q1 2022 earnings per share estimates for shares of Lantheus in a research report issued to clients and investors on Tuesday, April 12th. Jefferies Financial Group analyst Z. Weiner now anticipates that the medical equipment provider will post earnings per share of $0.42 for the quarter, down from their previous estimate of $0.47. Jefferies Financial Group also issued estimates for Lantheus’ Q2 2022 earnings at $0.44 EPS, Q3 2022 earnings at $0.44 EPS, FY2022 earnings at $1.81 EPS and FY2023 earnings at $2.07 EPS.

Lantheus (NASDAQ:LNTHGet Rating) last issued its quarterly earnings data on Thursday, February 24th. The medical equipment provider reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.17 by $0.08. The firm had revenue of $129.60 million for the quarter, compared to the consensus estimate of $111.77 million. Lantheus had a negative net margin of 16.76% and a positive return on equity of 6.80%. The company’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.07 EPS.

A number of other equities research analysts have also recently commented on LNTH. SVB Leerink increased their target price on shares of Lantheus from $34.00 to $75.00 and gave the company an “outperform” rating in a research report on Thursday, February 24th. StockNews.com initiated coverage on shares of Lantheus in a research note on Thursday, March 31st. They set a “hold” rating for the company. Truist Financial initiated coverage on shares of Lantheus in a report on Tuesday. They issued a “buy” rating and a $77.00 price objective for the company. Finally, Zacks Investment Research upgraded shares of Lantheus from a “sell” rating to a “buy” rating and set a $32.00 price objective for the company in a report on Thursday, February 24th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Lantheus has a consensus rating of “Buy” and a consensus price target of $51.00.

LNTH stock opened at $60.28 on Friday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.61 and a quick ratio of 2.22. The firm’s fifty day simple moving average is $46.63 and its 200-day simple moving average is $33.54. Lantheus has a 12 month low of $19.30 and a 12 month high of $61.26. The company has a market capitalization of $4.11 billion, a P/E ratio of -57.41, a price-to-earnings-growth ratio of 0.87 and a beta of 0.95.

Hedge funds have recently made changes to their positions in the stock. Maryland State Retirement & Pension System lifted its stake in shares of Lantheus by 1.5% during the fourth quarter. Maryland State Retirement & Pension System now owns 26,986 shares of the medical equipment provider’s stock valued at $780,000 after acquiring an additional 386 shares during the period. O Shaughnessy Asset Management LLC increased its holdings in Lantheus by 20.7% in the third quarter. O Shaughnessy Asset Management LLC now owns 5,056 shares of the medical equipment provider’s stock valued at $130,000 after purchasing an additional 866 shares during the last quarter. Diversified Trust Co increased its holdings in shares of Lantheus by 7.3% in the fourth quarter. Diversified Trust Co now owns 14,011 shares of the medical equipment provider’s stock worth $405,000 after acquiring an additional 955 shares in the last quarter. Advisor Group Holdings Inc. increased its holdings in shares of Lantheus by 6.2% in the fourth quarter. Advisor Group Holdings Inc. now owns 17,576 shares of the medical equipment provider’s stock worth $507,000 after acquiring an additional 1,031 shares in the last quarter. Finally, First Manhattan Co. increased its holdings in shares of Lantheus by 39.5% in the third quarter. First Manhattan Co. now owns 4,324 shares of the medical equipment provider’s stock worth $111,000 after acquiring an additional 1,224 shares in the last quarter. 95.27% of the stock is currently owned by institutional investors and hedge funds.

In other Lantheus news, CEO Mary Anne Heino sold 43,909 shares of the firm’s stock in a transaction dated Monday, February 28th. The stock was sold at an average price of $46.50, for a total transaction of $2,041,768.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Andrea Sabens sold 1,242 shares of Lantheus stock in a transaction dated Tuesday, January 18th. The shares were sold at an average price of $26.93, for a total value of $33,447.06. The disclosure for this sale can be found here. Insiders sold 112,860 shares of company stock valued at $5,630,110 in the last ninety days. 1.60% of the stock is owned by corporate insiders.

About Lantheus (Get Rating)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

Further Reading

Earnings History and Estimates for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.